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Abstract 
The aim of the present study was to analyze the potential role of substance P (SP) in 
gastric mucosal defense and to clarify the receptors and mechanisms, that may be involved in 
it. Gastric ulceration was induced by oral administration of acidified ethanol in male Wistar 
rats. Mucosal levels of calcitonin gene-related peptide (CGRP) and somatostatin were 
determined by radioimmunoassay. For analysis of gastric motor activity the rubber balloon 
method was used. We found that central (intracerebroventricular) injection of SP (9.3 - 74 
pmol) dose-dependently inhibited the formation of ethanol-induced ulcers, while 
intravenously injected SP (0.37-7.4 nmol/kg) had no effect. The mucosal protective effect of 
SP was inhibited by pretreatment with neurokinin 1-, neurokinin 2-, neurokinin 3- and -
opioid receptor antagonists, while - and -opioid receptor antagonists had no effect. 
Endomorphin-2 antiserum also antagonized the SP-induced mucosal protection. In the 
gastroprotective dose range SP failed to influence the gastric motor activity. Inhibition of 
muscarinic cholinergic receptors, or the synthesis of nitric oxide or prostaglandins 
significantly reduced the effect of SP. In addition, centrally injected SP reversed the ethanol-
induced reduction of gastric mucosal CGRP content. It can be concluded, that SP may induce 
gastric mucosal protection initiated centrally. Its protective effect is likely to be mediated by 
endomorphin-2, and vagal nerve may convey the centrally initiated protection to the 
periphery, where both prostaglandins, nitric oxide and CGRP are involved in mediating this 
effect. 
 
Key words: calcitonin gene-related peptide, endomorphin, gastric ulcer, substance P, 
tachykinins 
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1. Introduction 
Substance P (SP) is an undecapeptide belonging to the family of tachykinins, that is 
characterized by a common carboxy-terminal amino acid sequence (Phe-X-Gly-Leu-Met-
NH2, where X is an aromatic or hydrophobic residue). Substance P is encoded by the 
tachykinin precursor 1 (TAC1) gene, originally known as preprotachykinin (PPT)-A or PPT-I 
and represents the major endogenous ligand for the neurokinin receptor 1 (NK1), though it 
possesses appreciable affinity also for the other two tachykinin receptor subtypes, NK2 and 
NK3 (Harrison and Geppetti, 2001; Pantaleo et al., 2010). 
SP is highly abundant in the gastrointestinal (GI) tract, and acts both as a 
neurotransmitter and neuromodulator. The major source of SP is the intrinsic enteric neurons, 
but a smaller amount is contained in capsaicin-sensitive extrinsic afferents as well, where it is 
co-expressed with neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) (Holzer 
and Holzer-Petsche, 1997). CGRP has a prominent role in the maintenance of gastric mucosal 
integrity (Holzer, 2007) and NKA and its analogues have also been shown to induce 
gastroprotection after peripheral administration (Evangelista et al., 1989; Stroff et al., 1996). 
In contrast, SP given peripherally either did not affect ethanol-induced mucosal lesions 
(Evangelista et al., 1989; Stroff et al., 1996), or even aggravated it, probably through a 
mechanism involving reduced mucosal blood flow, mast cell degranulation and formation of 
reactive oxygen species (Gazzieri et al., 2007; Karmeli et al., 1991). 
Besides the periphery, gastric mucosal defense can also be induced by central 
mechanisms (for reviews see Gyires, 2004; Taché, 2012). Dorsal vagal complex (DVC) and 
vagal nerve were shown to play a crucial role in conveying the centrally initiated 
gastroprotective effect to the periphery (Kato et al., 1994; Yang et al., 1999). Moreover, 
hypothalamic paraventricular nucleus and lateral hypothalamus also take part in the central 
control of gastric functions, like acid secretion, motility and gastric mucosal defense (Grijalva 
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and Novin, 1990). SP is widely distributed in the central nervous system (Mantyh, 2002), and 
high density of both SP and NK1 receptors were shown in the above-mentioned areas (Dixon 
et al., 1998; Larsen, 1992; Lewis and Travagli, 2001, Haller, 2012), suggesting that SP 
besides its widespread role in mediation/modulation of central mechanisms, may play a role 
in the regulation of GI functions. Indeed, direct injection of SP into the dorsal motor nucleus 
of the vagus (DMV) (Krowicki and Hornby, 2000) or into the nucleus of the solitary tract 
(NTS) (Spencer and Talman, 1986) was shown to inhibit gastric motor activity and activation 
of NK1 receptors in the DVC reduced the medullary TRH-induced stimulation of gastric acid 
secretion (Yang and Taché, 1997). However, very limited data are available on the role of SP 
in central regulation of gastric mucosal integrity. To our best knowledge only one paper has 
been published on the central effect of SP on gastric ulcer formation, demonstrating that SP 
injected intracisternally inhibited the development of gastric ulcer formation in an acid-
dependent ulcer model, the cold-restraint stress-induced gastric ulceration, but the mechanism 
of the gastroprotective effect has not been clarified (Hernandez et al., 1983). 
Therefore the present study aimed to investigate: 
1) the effect of centrally injected SP on an acid-independent ulcer model (to exclude 
the potential role of inhibition of gastric acid secretion in the gastroprotective action), and to 
clarify the receptors that may mediate this effect, 
2) the peripheral, mucosal factors (altered motility, release of local mediators or 
neuropeptides) that may contribute to the gastroprotective effect of SP. 
 
2. Materials and methods 
2.1. Animals. 
For all experiments male Wistar rats were used. The rats were deprived of food for 24 
h with free access to tap water. They were housed in wire mesh bottom cages to prevent 
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coprophagy. The rats were kept on a 12 h light-dark cycle and under conditions of controlled 
temperature. 
All procedures conformed to the European Convention for the protection of vertebrate 
animals used for experimental and other scientific purposes. The study was approved by the 
Animal Ethics Committee of Semmelweis University, Budapest (permission number: 
22.1/606/001/2010). 
2.2. Gastric mucosal damage induced by acidified ethanol. 
For ethanol ulcer experiments 140-170 g rats were used. After 24 h food deprivation 
the animals were given orally 0.5 ml acidified ethanol (98 ml absolute ethanol + 2 ml 
concentrated HCl). One hour later the animals were euthanized, the stomachs were excised, 
opened along the greater curvature, rinsed with saline and examined for lesions. Total number 
of mucosal lesions was assessed in blinded manner by calculation of the ulcer index (U.I.) 
based on a 0-4 scoring system described previously (Gyires, 1990). The ulcer index was 
calculated as the total number of lesions multiplied by the respective severity factor. The 
percentage inhibition of mucosal damage was calculated as follows: 
 
 
 
U.I. in treated group
U.I. in control group
100 1  
SP was injected either intracerebroventricularly (i.c.v.) 10 min before the ethanol 
challenge in a volume of 10 μl, or intravenously (i.v., via the tail vein) in a volume of 0.5 
ml/100 g 15 min before the administration of ethanol, as described previously (Gyires et al., 
2000). Antagonists were given either together with the agonists (if both were injected i.c.v), 
or 15 and 60 min (i.v. and oral administration, respectively) before injecting the agonist. 
2.3. In vivo measurement of gastric motor activity. 
For in vivo measurement of gastric motility the rubber balloon method was used 
(LeFebvre et al., 1992). Briefly, after 24 h food deprivation 250-400 g male Wistar rats were 
anesthetized with urethane (1.25 g/kg i.p.), a tracheal cannula was inserted to ensure a clear 
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airway and an intragastric balloon created from thin latex rubber connected with plastic 
tubing was introduced into the stomach via mouth. The balloon was filled with 2 ml warm 
water (37°C) to set the basal intragastric pressure to 10 ± 0.5 cmH2O. The exact location of 
the balloon was verified after each experiment. The distal end of tubing was connected to a 
pressure transducer and to a PowerLab Instrument with a Chart 5 program (AdInstruments, 
Bella Vista, Australia) to monitor the intragastric balloon pressure. A 15-30 min equilibrium 
period was registered before every experiments. SP was given i.c.v. in a volume of 10 μl 
within 5 min, injected with a CMA/100 microinjection pump. For i.c.v injection guide 
cannulas (Bilaney Consultants, Düsseldorf, Germany) were implanted under pentobarbital 
anesthesia (35 mg/kg i.p.) with stereotaxic surgery (Stoelting, Illinois, USA) 5 days before the 
analysis of motility. Coordinates for the guide cannulas relative to bregma are as follows: 
posterior 0.8 mm; lateral 1.6 mm; ventral 4.5 mm (Paxinos and Watson, 1986). The guide 
cannulas were fixed with dental cement (Adhesor Cement, Spofa Dental, Jičín, Czech 
Republic). The site of the injection was verified after each experiment. 
For analysis of gastric motor activity two parameters were determined. The gastric 
tone, which correlates well with fundic activity (Ferreira Jr. et al., 2002), was calculated from 
the bottom points of phasic pressure wave. The mean amplitude of phasic contractions, which 
correlates with the antral contractions superimposed on tonic pressure, was calculated from 
the amplitude of each contraction. Both parameters were determined from 5 min segments, 
before and after the injection of SP (Zádori et al., 2007). Values were expressed in percentage 
of the basal (pre-injection) values. 
2.4. Radioimmunoassay determinations. 
For determination of gastric mucosal level of CGRP and somatostatin the rats were 
euthanized, the stomachs were removed and gastric mucosa was separated on a cooled plate. 
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It was weighed and put in 1 ml cold distilled water, sonicated and stored at -80 ºC till the 
determination. 
CGRP and somatostatin concentrations were determined by radioimmunoassay (RIA) 
described previously (Németh et al., 1996, 1998). For the specific RIA assays the antisera 
(CGRP: C1012; somatostatin: 775/7) were raised in rabbit or in case of somatostatin in sheep 
immunized with synthetic peptides conjugated to thyroglobulin by glutaraldehyde. The tracers 
were mono-125l-labelled peptides prepared by Németh et al. (2002). Synthetic peptides were 
used as RIA standards ranging from 0 to 1000 fmol/ml (somatostatin RIA) and from 0 to 100 
fmol/ml (CGRP RIA). Detection limits of the assays were 2 fmol/ml (somatostatin) and 0.2 
fmol/ml (CGRP). These techniques have proved to be specific, sensitive and valid for the 
measurement of neuropeptides in pharmacological research. Peptide concentrations were 
calculated as the measured amount of peptide per wet tissue weight, expressed as fmol/mg. 
2.5. Materials. 
 The following drugs were used: naloxone hydrochloride, naltrindole hydrochloride, 
nor-Binaltorphimine dihydrochloride (norBNI), N
G
-nitro-L-arginine (L-NNA), indomethacin, 
atropine sulphate (all purchased from Sigma Chemical Co., St. Louis, USA), substance P 
(Ascent Scientific, Bristol, UK), -funaltrexamine hydrochloride, L-733,060 hydrochloride 
((2S,3S)-3-[[3,5-bis(Trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine hydrochloride), 
GR 159897 (5-Fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulphinyl]methyl]-1-piperidinyl]ethyl]-
1H-indole), SB 222200 (3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinoline-
carboxamide) (all from Tocris Bioscience, Bristol, UK) and EM-2 antiserum (produced by 
István Barna, Hungarian Academy of Sciences). 
 All drugs were dissolved in saline, with the exception of indomethacin, which was 
suspended in 1% methylcellulose, and the NK2- and NK3-receptor antagonists (GR 159897 
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and SB 222200), which were dissolved in DMSO and then diluted with saline. Control 
animals received the drug solvents. 
 For the receptorial analysis the doses of antagonists were selected based partly on our 
previous experiments, party on the literature data (Table 1). 
 No data have been published to our knowledge on the i.c.v. dose of L-733,060 and GR 
159897 in rats, however a wide dose range (from picomolar to micromolar: Pacharinsak et al., 
2008; Rittner et al., 2007; Walsh et al., 1995) was used in the case of other routes of 
administration. The applied doses in the present study (1 nmol for L-733,060 and 0.5 nmol for 
GR 159897) were based partly on our preliminary results, partly on the estimated affinity of 
these ligands for the NK1 and NK2 receptors, respectively, derived from in vitro studies 
(Beresford et al., 1995; Seabrook et al., 1996). 
 The properties of EM-2 antiserum have been described previously in detail 
(Szemenyei et al., 2008). The antiserum was used at a 20-fold final dilution. The same 
dilution of non-reactive rabbit serum (NRS) was used as control. 
2.6. Statistical analysis. 
Statistical analysis of the data was evaluated by means of analysis of variance 
(ANOVA) followed by Newman-Keuls test for multiple comparisons. In the case of motility 
experiments the pre- and postinjection values were compared with paired Student’s t-test. A 
probability value of less than 0.05 was considered statistically significant. 
 
3. Results 
3.1. The effect of SP on the ethanol-induced gastric mucosal damage. 
Oral administration of acidified ethanol induces deep, multiple longitudinal 
hemorrhagic lesions on the gastric mucosa (Fig. 1, ulcer index: 97 ± 7, n=10). SP, when 
injected i.c.v., significantly decreased the formation of ethanol induced gastric mucosal 
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lesions in the doses of 4.6-148 pmol/rat (Fig. 1 and 2A). The maximal inhibition was induced 
by 9.3 and 18.5 pmol (89.8 and 75.8 %, respectively), and the latter dose was chosen for 
further experiments. At higher dose range (74 and 148 pmol), however, the gastroprotective 
effect of SP declined (33.0 and 29.4 % inhibition). 
In contrast, SP injected intravenously in the doses of 0.37-7.4 nmol/kg (0.5-10 μg/kg) 
failed to inhibit the development of gastric mucosal lesions. The two lowest doses (0.37 and 
0.74 nmol/kg) resulted in a slight increase of ulcer index (24.4 and 27.4 %, respectively), 
however, the difference was not statistically significant (Fig. 1 and 2B). 
3.2. The effect of SP on the gastric motor activity. 
 SP given i.c.v. in the gastroprotective dose range did not influence the gastric motor 
activity (Table 2). At the highest dose (740 pmol) it reduced slightly the amplitude of 
contractions (24 % inhibition), but it was not statistically significant (p=0.14, pre- vs 
postinjection values, paired t-test). 
3.3. The effect of tachykinin receptor antagonists on the gastroprotective effect of SP. 
 The effect of i.c.v. injected L-733,060 (1 nmol/rat), GR 159897 (0.5 nmol/rat) and SB 
222200 (1 nmol/rat), potent, selective non-peptide antagonists of the NK1, NK2 and NK3 
receptors, respectively, was studied on the protective effect of SP (18.5 pmol/rat, i.c.v.). As 
Fig. 3 demonstrates, all three antagonists reversed the effect of SP. Alone they did not modify 
the ethanol-induced mucosal damage. 
3.4. Analysis of the role of opioid system in the gastroprotective effect of SP. 
 I.c.v. injection of the non-selective opioid receptor antagonist naloxone (27 nmol/rat) 
induced a slight, non-significant reduction of mucosal ulcers (ulcer indices: 110 ± 10 vs 83 ± 
13, n=5). When it was injected together with SP (18.5 pmol/rat), the SP-induced 
gastroprotection significantly decreased (Fig. 4A). Similar results were obtained with the 
selective -opioid receptor antagonist -funaltrexamine (20 nmol/rat, Fig. 4B). In contrast, 
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neither the selective δ-opioid receptor antagonist naltrindole (5 nmol/rat), nor the selective κ-
opioid receptor antagonist norbinaltorphimine (norBNI, 14 nmol/rat) inhibited the central 
gastroprotective effect of SP (Fig. 4C and 4D). 
 Since these results strongly suggest the involvement of μ-opioid receptors in the 
protective effect of SP, in the next set of experiments the interaction between EM-2 
(endogenous ligand of μ-opioid receptors) and SP was analyzed. Antiserum against EM-2 was 
co-injected with SP, which completely reversed the protective effect of the latter compound. 
EM-2 antiserum injected alone had no effect on the ulcer index, neither the non-reactive 
rabbit serum, which was used as control (Fig. 4E). 
3.5. Analysis of the peripheral factors mediating the central gastroprotective effect of SP. 
 Blockade of muscarinic cholinergic receptors by atropine (1 mg/kg i.v., Fig. 5A), the 
prostaglandin synthesis by indomethacin (20 mg/kg p.os., Fig. 5B) and the nitric oxide 
synthesis by L-NNA (3 mg/kg i.v., Fig. 5C) all significantly reduced the mucosal protective 
effect of SP. 
 CGRP and somatostatin levels of the gastric mucosa were also measured with 
radioimmunoassay. Acidified ethanol given orally dramatically decreased the mucosal 
concentration of both CGRP and somatostatin. Centrally injected SP (18.5 pmol/rat) almost 
completely reversed the effect of ethanol on the CGRP level (Fig. 6A), and caused a slight 
elevation of the somatostatin concentration as well, although this effect was not significant 
(Fig. 6B). In contrast, i.v. administered SP (0.74 nmol/kg) failed to influence the ethanol-
induced reduction of mucosal CGRP and somatostatin. 
 
4. Discussion 
It was first demonstrated that centrally (i.c.v.) injected substance P induces 
gastroprotective effect and inhibits the direct necrotizing action of acidified ethanol. We 
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found that SP was effective only in lower dose range (9.3 - 37 pmol i.c.v.), while at higher 
doses the gastroprotective effect diminished. It might be speculated that SP in high dose may 
act not only in the central nervous system, but also in the periphery, and induces such 
mechanisms which counteract its protective action, e.g. reduced mucosal blood flow, mast 
cell degranulation or formation of reactive oxygen species (Gazzieri et al., 2007; Karmeli et 
al., 1991; Yokotani and Fujiwara, 1985). Similar bell-shaped dose-response curve has been 
observed at other SP-induced effects as well, like in supraspinal antinociception (Frederickson 
et al., 1978), in improvement of learning and memory (Kertes et al., 2009) or in the case of its 
anxiolytic-like effect (Hasenöhrl et al., 1998). It is also worthy of note that the bell-shaped 
dose response relationship is not a unique property of SP, it has also been described for 
several other neuropeptides, for example for nociceptin, nocistatin, β-endorphin or 
somatostatin (Gyires et al., 2000; Hernandez et al., 1983; Zádori et al., 2008). 
As mentioned above, in contrast with the centrally induced effect, SP given i.v., i.p. or 
s.c. either failed to reduce ethanol-induced mucosal damage (Evangelista et al., 1989), or 
aggravated it (Gazzieri et al., 2007; Karmeli et al., 1991). In our experimental model i.v. 
injected SP had no significant effect on the ethanol-induced lesions. 
Although the terms “gastric cytoprotection” and “gastroprotection” are used since 
decades (Robert et al., 1979; Rainsford and Whitehouse, 1980; Szabó et al., 1981), and refer 
to the ability of various compounds to prevent the formation of gastric ulcers without 
influencing gastric acid secretion, the exact mechanism of this gastroprotective effect is still 
not clear, though several peripheral and central factors have already been reported to be 
involved in it (Mózsik et al., 2011). The main purpose of this study was to clarify, which 
mechanisms may be responsible for the mucosal protective effect of SP. First we analyzed the 
involvement of the central NK receptors. Since SP is the ligand of NK1 receptors primarily, 
we supposed that the SP-induced mucosal protection is mediated by the NK1 receptors. 
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However, our results suggest that besides NK1 receptors, NK2 and NK3 receptors may also 
mediate the effect. These results are in agreement with the findings that demonstrate the 
presence of all three tachykinin receptors in the DVC (Dixon et al., 1998; Mazzone and 
Geraghty, 2000), a key region in the central modulation of GI functions. Although the 
involvement of NK2 and/or NK3 receptors in the central effect of SP is unexpected, it is not 
unprecedented. For example, it was observed that both NK1 and NK2 receptors are involved 
in the excitatory effect of SP on neurons of the DMV projecting to the stomach (Lewis and 
Travagli, 2001) and both NK2 and NK3 receptors seem to mediate the inhibitory effect of SP 
on pancreatic ductal bicarbonate secretion (Kemény et al., 2011). Moreover, all three 
tachykinin receptors mediate the postsynaptic action of SP on rat periaqueductal grey neurons 
in vitro (Drew et al., 2005). 
The ability of central NK2 receptors to regulate gastric acid secretion and mucosal 
integrity is also supported by the findings of Improta et al. (1997), who found that the 
selective NK2 agonist Ala
5
NKA(4-10) injected i.c.v. reduced the secretion of gastric acid and 
the formation of mucosal lesions in an acid-dependent ulcer model (pylorus ligation) in rats. 
It also can be raised that SP by activating NK1 receptors may release other 
endogenous tachykinins, that activate NK2 and NK3 receptors. The DVC in rats is enriched 
with axon terminals containing NKA and NKB (Colin et al., 2002), and the activation of NK1 
receptors in the NTS has been shown to increase the release of glutamate (Bailey et al., 2004), 
which, in turn can lead to the release of neurokinins (Colin et al., 2002). However, further 
studies are needed to clarify, whether the release of NKA and NKB is involved in the 
gastroprotective effect of SP. 
Correlation between gastric motor activity and gastric mucosal protection has been 
described, namely, inhibition of gastric motility may result in flattening of the mucosal 
foldings and decrease the mucosal vulnerability to irritants. The inhibition of gastric motor 
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activity may contribute to the gastroprotective effect of amylin (Guidobono et al., 1998), 
dopamine or capsaicin (Takeuchi et al., 1988, 1991). Direct injection of SP (135 - 405 pmol) 
into the DMV (Krowicki and Hornby, 2000) or into the NTS (Spencer and Talman, 1986) has 
been reported to inhibit gastric motor activity, therefore we investigated, whether the effect of 
SP on gastric motility may play a role in its gastroprotective effect. We found that i.c.v. 
injection of SP in the gastroprotective dose-range (7.4 and 74 pmol) did not induce any 
significant action on gastric motility. Furthermore, it caused even at 10 times higher dose 
(740 pmol) only a moderate reduction of gastric contractions. Thus, it is unlikely that 
inhibition of gastric motility would have any relevance in the gastroprotective effect of SP. 
Our result is in good correlation with the findings of Improta and Broccardo (1990), who 
found that SP given i.c.v. inhibited only moderately the gastric emptying even in a high dose 
(6 nmol). 
Centrally administered SP has been reported to inhibit feeding behaviour in both rats 
(Dib, 1999) and recently in chicks (Tachibana et al., 2010). Several orexigenic and 
anorexigenic gut hormones (e.g. amylin, peptide YY, ghrelin, leptin, cholecystokinin) have 
been shown to inhibit gastric mucosal ulceration in both acid-dependent and independent 
ulcer models (reviewed by Gyires, 2004; Taché, 2012). Though, it can be speculated that the 
altered feeding status and gastrointestinal motility is related to their mucosal protective effect 
physiologically, it is not likely that the effect of SP on feeding behaviour plays a role in its 
gastroprotective effect. Especially as the anorexigenic effect of SP could be observed only at 
higher (nanomolar) dose range, while the gastroprotective action could be induced by 
picomolar doses. 
The possible role of the endogenous opioids has also been analyzed in the central 
gastroprotective action of SP, because several lines of evidence suggest that SP may be able 
to release endogenous opioids (Kream et al., 1993; Naranjo et al., 1986; Parenti et al., 2012), 
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and opioids have been shown to induce gastroprotection by central mechanism in much lower 
doses than those required to induce antinociceptive effect (Gyires et al., 2013; Gyires and 
Rónai, 2001; Al-Khrasani et al., 2012). Moreover, endogenous opioids are likely to mediate 
the gastroprotective effect of several compounds, like clonidine (Gyires et al., 2000), 
nociceptin, nocistatin (Zádori et al., 2008) and cannabinoids (Shujaa et al., 2009). 
In accordance with the above data, the mucosal protective effect of SP was 
significantly reduced by pretreatment with naloxone, suggesting that the release of 
endogenous opioids is indeed one potential link in the chain of events resulting in 
gastroprotection. It is noteworthy, that in the study of Kream et al. (1993) the potential opioid 
releasing effect of SP could be observed at exactly the same dose-range (10-100 pmol), that 
induced gastroprotection in our experiments (9.3-74 pmol). 
Because the -opioid receptor antagonist -funaltrexamine also antagonized the effect 
of SP, while the δ- and κ-opioid receptor antagonist naltrindole and norbinaltorphimine, 
respectively, failed to affect it, we raised the hypothesis that SP may release the highly 
selective μ-opioid receptor agonist endomorphins (Zadina et al., 1997), that mediate the 
gastroprotective effect. Endomorphins are widely distributed in the CNS, also in several 
hypothalamic nuclei and in the NTS (Martin-Schild et al., 1999). Their co-localization with 
SP and CGRP in primary sensory neurons and different brain regions is supposed to provide a 
complex control of the transmission of nociceptive and autonomic informations (Greenwell et 
al., 2007), which is also supported by the findings showing that the binding of endomorphins 
to μ-opioid receptors may be influenced by TRPV1 receptors (Wollemann et al., 2013). 
Our experiments focused on the potential role of EM-2, because it is more abundant in 
the lower brain stem compared to EM-1 (Martin-Schild et al., 1999), and it has been shown to 
be co-localized with SP in the NTS (Greenwell et al., 2007). As our present results 
demonstrate, pretreatment with EM-2 antiserum resulted in inhibition of the protective effect 
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of SP, suggesting that among the endogenous opioids EM-2 is likely to have an essential role 
in the SP-induced action. 
In the last step we investigated, how the SP-induced protective effect is conveyed to 
the periphery. Several neuropeptides have been shown to exert gastroprotective action after 
central administration, e.g. adrenomedullin, thyrotropin-releasing hormone or peptide YY in a 
vagal dependent mechanism (Kaneko et al., 1998; Kato et al., 1994; Yang et al., 1999). 
Namely, dual effects of the vagal nerve have been described; activation of vagal efferents 
beside stimulation of gastric acid secretion, may induce gastric mucosal prostaglandin and 
NO production as well as activation of efferent function of capsaicin-sensitive afferent fibers 
containing CGRP (Gyires, 2004; Taché, 2012). 
As our results demonstrate, blockade of muscarinic cholinergic receptors by peripheral 
injection of atropine, inhibition of gastric prostaglandin synthesis by oral administration of 
indomethacin and intravenous injection of the NO synthase inhibitor L-NNA all abolished the 
mucosal protective effect of SP. 
Moreover, the mucosal content of CGRP was dramatically decreased after oral 
administration of acidified ethanol in agreement with the findings of Evangelista et al. (1993). 
CGRP, as mentioned above, has a major role in the maintenance of gastric mucosal integrity 
via increasing mucosal blood flow partly directly by acting on vascular smooth muscle, partly 
indirectly, by releasing NO (Holzer et al., 1993) and somatostatin (Bunnett et al., 1990). As 
our result show, i.c.v., but not i.v. injected SP almost completely reversed the detrimental 
effect of acidified ethanol on gastric mucosal CGRP content. 
The mucosal somatostatin level similarly to that of CGRP dramatically decreased after 
the ethanol challenge. However, SP failed to reverse the reduced somatostatin level in the 
gastric mucosa suggesting that somatostatin may not be involved or has only minor role in the 
CGRP-mediated gastric mucosal protective action. 
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5. Conclusions 
In summary, the present results indicate that SP given i.c.v. in picomolar dose-range 
exerts a strong gastroprotective action, which is mediated by all the three (NK1, NK2 and 
NK3) neurokinin receptors, and - at least partly - by the endogenous opioid system and EM-2. 
This centrally initiated effect is conveyed to the periphery by a vagal-dependent pathway, and 
in the gastric mucosa CGRP, prostaglandins and NO may mediate the mucosal defense. 
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Figure captions 
Fig. 1. 
 Macroscopic picture of the acidified ethanol-induced gastric mucosal damage in rats 
treated either with saline, or with substance P i.c.v. (18.5 pmol/rat) or i.v. (0.74 nmol/kg). 
Acidified ethanol was given orally 10 min after the i.c.v. injection. The dark, livid areas 
represent the hemorrhagic ulcerous part of the mucosa. 
 
Fig. 2. 
 The inhibitory effect of substance P on ethanol-induced gastric mucosal injury in rats. 
SP was injected either intracerebroventricularly (i.c.v., 4.6-148 pmol/rat, Fig. 2A) or 
intravenously (i.v., 0.37-7.4 nmol/kg, Fig. 2B) 10 and 15 min before the ethanol challenge, 
respectively. Each column represents mean ± S.E.M., the number of animals was 5 per group. 
*P<0.05, **P<0.01; ***P<0.001 (ANOVA, Newman-Keuls post hoc test, compared with the 
respective control group). 
 
Fig. 3. 
 The effect of L-733,060 (L-733, 1 nmol/rat i.c.v., Fig. 3A), GR 159897 (GR, 0.5 
nmol/rat i.c.v., Fig. 3B) and SB 222200 (SB, 1 nmol/rat i.c.v., Fig. 3C) on the 
gastroprotective effect of substance P (SP, 18.5 pmol/rat i.c.v.). SP was injected 10 min 
before the ethanol challenge either alone, or in combination with the different antagonists. 
Each column represents mean ± S.E.M., n=5; ***P<0.001 compared with vehicle-treated 
group (column 1); 
†††
P<0.001 compared with SP-treated group (column 2) (ANOVA, 
Newman-Keuls post hoc test). 
 
Fig. 4. 
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 The effect of naloxone (NX, 27 nmol/rat i.c.v., Fig. 4A), -funaltrexamine (-FNA, 20 
nmol/rat, Fig. 4B), naltrindole (Nalt, 5 nmol/rat i.c.v., Fig. 4C), norbinaltorphimine (norBNI, 
14 nmol/rat i.c.v., Fig. 4D) and endomorphin-2 antiserum (EM-2 AS, Fig. 4E) on the 
gastroprotective effect of substance P (SP, 18.5 pmol/rat i.c.v.). SP was injected 10 min 
before the ethanol challenge either alone (dissolved in saline or in non-reactive rabbit serum 
(NRS)), or in combination with the antagonists (opioid receptor antagonists or endomorphin-2 
antiserum). 
Each column represents mean ± S.E.M., n=5; **P<0.01, ***P<0.001 compared with saline-
(or NRS-) treated group (column 1); 
†
P<0.05, 
†††
P<0.001 compared with SP-treated group 
(column 2), 
#
P<0.05, 
##
P<0.01, 
###
P<0.001 compared with antagonist-treated group (column 
3) (ANOVA, Newman-Keuls post hoc test). 
 
Fig. 5. 
 The effect of atropine (Atr, 1 mg/kg i.v., Fig. 5A), indomethacin (Indo, 20 mg kg p.os, 
Fig. 5B), and N
G
-nitro-L-arginine (L-NNA, 3 mg/kg i.v., 5C) on the gastroprotective effect of 
substance P (SP, 18.5 pmol/rat i.c.v.). SP was injected 10 min before the ethanol challenge, 
the antagonists were given 15 min (i.v.) or 60 min (p.os) before the administration of SP. 
Each column represents mean ± S.E.M., n=5; *P<0.05, ***P<0.001 compared with vehicle-
treated group (column 1); 
†††
P<0.001 compared with SP-treated group (column 2) (ANOVA, 
Newman-Keuls post hoc test). 
 
Fig. 6. 
The effect of substance P (SP) on the mucosal CGRP (Fig. 6A) and somatostatin 
concentration (Fig. 6B). SP was injected either intracerebroventricularly (i.c.v., 18.5 pmol/rat) 
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or intravenously (i.v., 0.74 nmol/kg). CGRP and somatostatin concentrations were determined 
by radioimmunoassay (RIA). 
Each column represents mean ± S.E.M., n=5; *P<0.05, ***P<0.001 compared with control 
group (no ethanol treatment, column 1); 
††
P<0.01 compared with ethanol+saline i.c.v.-treated 
group (column 3) (ANOVA, Newman-Keuls post hoc test). 
1. Substance P via acting on central NK1-3 receptors induces gastroprotection. 
2. Endomorphin-2 is likely to play a role in the SP-induced gastroprotective effect. 
3. The centrally induced effect is mediated by the vagal nerve to the periphery. 
4. In the periphery prostaglandins, nitric oxide and CGRP mediate the effect. 
5. Alterations in gastric motor activity do not contribute to the gastroprotection. 
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Table 1.  
The list of antagonists and their doses. 
Antagonist Route of 
administration 
Applied dose Reference 
Atropine i.v. 1 mg/kg Gyires et al. 2000 
-funaltrexamine i.c.v. 20 nmol/rat Zádori et al. 2008 
GR 159897 i.c.v. 0.5 nmol/rat - 
Indomethacin p. os 20 mg/kg Gyires & Rónai 
2001 
L-733,060 i.c.v. 1 nmol/rat - 
L-NNA i.v. 3 mg/kg Gyires & Rónai 
2001 
Naloxone i.c.v. 27 nmol/rat Zádori et al. 2008 
Naltrindole i.c.v. 5 nmol/rat Zádori et al. 2008 
Nor-Binaltorphimine i.c.v. 14 nmol/rat Zádori et al. 2008 
SB 222200 i.c.v. 1 nmol/rat Haley & Flynn 2007 
 
Table 1
Table 2.  
The effect of SP given intracerebroventricularly on the gastric motor activity. 
Values indicate the percentage of the baseline (preinjection) value. 
 
 
 
 
Treatment 
Gastric tone 
(%) 
Mean Amplitude of 
contractions (%) 
n 
Saline i.c.v. 100 ± 1 99 ± 17 5 
SP 7.4 pmol i.c.v. 100 ± 1 98 ± 9 5 
SP 74 pmol i.c.v. 102 ± 3 99 ± 10 6 
SP 740 pmol i.c.v. 98 ± 2 76 ± 10 5 
Table 2
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